U.S. District Court Grants Summary Judgment for Axinn’s Client Zydus in FDA Case
May 27, 2015
Axinn attorneys, advocating on behalf of client Zydus Pharmaceuticals as a Defendant-Intervenor on the side of the U.S. Food and Drug Administration, won a summary judgment that affirms the FDA’s authority and practice of allowing specific label carve-outs by ANDA generic drug makers. The U.S. District Court in Maryland rejected Otsuka’s claim that the drug aripiprazole, which Otsuka markets under the name Abilify®, maintains market exclusivity from any generic use by virtue of its designation as an orphan drug for use in treating pediatric patients with Tourette’s disorder.
The price competition created by the entry of generic versions of this prescription drug into the marketplace will benefit consumers who require aripiprazole to effectively treat a myriad of other medical conditions.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ACI 12th Annual Summit for Women Leaders in Life Sciences Law
Speaking Engagement
Intellectual Property
National LGBTQ+ Bar Association Lavender Law Conference and Career Fair 2025
Sponsorship
National Bar Association 100th Annual Convention and Exhibits
Sponsorship
Antitrust
Keeping Pace: Updates in Cartel Enforcement
Webinar
Antitrust
New Incentives, New Rewards: What You Need to Know About the Antitrust Division’s First-Ever Whistleblower Rewards Program
Axinn Viewpoints
Antitrust
Informa Antitrust Midwest
Speaking Engagement
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
How I Made Partner: 'Show Up and Build Rapport With Colleagues and Clients,' Says Michael O'Mara of Axinn Veltrop & Harkrider
Media Mentions
Antitrust
Axinn Counsel Rebecca Clegg Named 2025 MCCA Rising Star
Awards & Recognitions
Intellectual Property
Chambers Merger Control 2025 Guide
Byline Articles
Antitrust